Study of a Single Dose of Danicopan in Healthy Participants
Status:
Completed
Trial end date:
2016-06-21
Target enrollment:
Participant gender:
Summary
This was a single ascending dose, randomized, double-blind study assessing the safety,
tolerability, pharmacokinetics, and pharmacodynamics of danicopan in healthy participants.
Four different doses (200 milligrams [mg], 600 mg, 1200 mg, 2400 mg) and dose-matched placebo
were administered under fasted and fed conditions.